Clinical Trial Update: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on the combination of ramucirumab and pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in Phase 1/Phase 2 coho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cyramza (ramucirumab)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING